Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13002130 | 0.77 | BCL2L1 (0.38) | KMT2ATSHRBCL2L1PDE4BPDE4D | |
| SCHEMBL13002139 | 0.70 | MEN1 (0.63) | MEN1KMT2APAK1CNR2HSP90B1 | |
| SCHEMBL10908310 | 0.69 | BCL2L1 (0.46) | MEN1KMT2ABCL2L1PDE4BPDE4D | |
| SCHEMBL10910975 | 0.69 | BCL2L1 (0.46) | MEN1KMT2ABCL2L1CNR1CNR2 | |
| SCHEMBL28035508 | 0.69 | KMT2A (0.60) | MEN1KMT2APDE4BPDE4DLMNA | |
| SCHEMBL31421665 | 0.69 | TYK2 (0.45) | MEN1KMT2ACYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL15904569 | 0.69 | TYK2 (0.45) | MEN1KMT2ACYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL1662996 | 0.69 | TSHR (0.41) | MEN1KMT2ATSHRBCL2L1PDE4B | |
| SCHEMBL11877723 | 0.69 | MEN1 (0.49) | MEN1KMT2APAK1TSHRLMNA | |
| SCHEMBL28449540 | 0.68 | MEN1 (0.50) | MEN1KMT2APAK1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846974-B2 | Method of lowering blood glucose and method of treating diabetes and obesity | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7846974-B2 | Method of lowering blood glucose and method of treating diabetes and obesity | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090111893-A1 | METHOD OF LOWERING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING DIABETES AND OBESITY | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111893-A1 | METHOD OF LOWERING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING DIABETES AND OBESITY | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111893-A1 | METHOD OF LOWERING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING DIABETES AND OBESITY | HBG1, GPR119, GCKR | MEN1 2556/4885KMT2A 1125/4885PAK1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.